Search PubMed⌕ Search

PubMed · 2077561

Cigarette classification as a consumer message.

Abstract

Cigarette yields of tar, nicotine, and carbon monoxide, obtained by standard smoking machine procedures, have been adopted as official consumer information throughout the world. However, real-life dynamics of cigarette puffing and inhalation are not standard, but follow widely fluctuating individual behavior. In addition, smokers inhale after puffing, an event that standard smoking machines do not address. Clearly then, analytical cigarette yields alone are insufficient as quantitative predictors of smoke intake valid for all smokers. Bioavailability studies show that virtually all cigarettes, regardless of analytical yield, can satisfy the nicotine demand of any smoker. On the other hand, tar intake and nicotine intake are related according to the tar-to-nicotine ratio of the smoke, which varies with brands. Thus, while a generalized message predictive of quantitative individual intake is not feasible, tar-to-nicotine ratios of standard analytical yields tell any smoker about expectations of proportional tar intake from different brands, and should be adopted as the preferred consumer message.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

G B Gori. 1990. Cigarette classification as a consumer message.. https://doi.org/10.1016/s0273-2300(05)80062-5

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Safety data on meningococcal polysaccharide vaccine from the Vaccine Adverse Event Reporting System.

Recent recommendations by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices may lead to the increased use of the meningococcal polysaccharide vaccine. The Vaccine Adverse Event Reporting System (VAERS) is useful for the detection of previously unrecognized reactions and for the monitoring of known reactions. Limitations of VAERS include underreporting and the inability to establish a causal relationship between vaccination and adverse events in most cases. From July 1990 through 31 October 1999, 110 adverse events were reported after receipt of meningococcal vaccine alone. Thirteen (12%) were serious, including 6 injection site reactions, 3 allergic reactions, 1 case of Guillain-Barré syndrome, and 3 miscellaneous events. Fever (30%), headache (17%), dizziness (15%), injection site hypersensitivity (13%), urticaria (12%), and paresthesia (10%) were among the most common events reported. Fever and injection site and allergic reactions are most likely causally linked to the vaccine. That there were few reports of serious adverse events, with >6 million doses having been distributed, and no clear signal of a previously unrecognized serious reaction is reassuring with regard to the safety of meningococcal vaccine.

Consumer Product Safety↗